Stockscreener 앱 받기
100.90
0.27%
0.27
전일 마감가:
$100.63
열려 있는:
$99.08
하루 거래량:
343.86K
Relative Volume:
0.42
시가총액:
$6.15B
수익:
$569.61M
순이익/손실:
$-23.36M
주가수익비율:
-7.4168
EPS:
-13.6043
순현금흐름:
$54.87M
1주 성능:
+3.53%
1개월 성능:
-3.29%
6개월 성능:
+8.45%
1년 성능:
+36.02%
1일 변동 폭
$99.08
$101.99
1주일 범위
$95.61
$101.99
52주 변동 폭
$63.23
$130.00
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
명칭
Mirum Pharmaceuticals Inc
전화
650-667-4085
주소
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
100.90 | 5.92B | 569.61M | -23.36M | 54.87M | -13.60 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-18 | 개시 | RBC Capital Mkts | Outperform |
| 2025-09-24 | 개시 | TD Cowen | Buy |
| 2025-08-11 | 재개 | Stifel | Buy |
| 2025-05-19 | 재개 | H.C. Wainwright | Buy |
| 2024-04-17 | 개시 | Stifel | Buy |
| 2023-12-18 | 재확인 | H.C. Wainwright | Buy |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-11-13 | 개시 | Morgan Stanley | Overweight |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-17 | 재개 | Evercore ISI | Outperform |
| 2023-09-20 | 개시 | JMP Securities | Mkt Outperform |
| 2022-09-01 | 개시 | Citigroup | Buy |
| 2021-09-20 | 개시 | JP Morgan | Overweight |
| 2020-08-07 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | 개시 | H.C. Wainwright | Buy |
| 2020-07-31 | 개시 | Piper Sandler | Overweight |
| 2020-06-25 | 개시 | Robert W. Baird | Outperform |
| 2019-08-12 | 개시 | Citigroup | Buy |
| 2019-08-12 | 개시 | Evercore ISI | Outperform |
| 2019-08-12 | 개시 | Guggenheim | Buy |
| 2019-08-12 | 개시 | ROTH Capital | Buy |
| 2019-08-12 | 개시 | Raymond James | Outperform |
모두보기
Mirum Pharmaceuticals Inc 주식(MIRM)의 최신 뉴스
MIRM5806400 Bond Profile — Key Metrics - TradingView
Citizens raises Mirum Pharmaceuticals price target to $146 - scanx.trade
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), Moderna (MRNA) and Merck & Company (MRK) - The Globe and Mail
H.C. Wainwright reiterates Mirum Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Lisanti Capital Growth LLC Takes Position in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
US FDA approves Regeneron's rare bone disorder drug - Reuters
Mirum Pharmaceuticals(MIRM.US) Officer Sells US$4 Million in Common Stock - Moomoo
Jolanda Howe Sells 40,000 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock - MarketBeat
Mirum Pharmaceuticals SVP, Global Controller Sold Shares Worth Over $4M - TradingView
Mirum Pharmaceuticals (MIRM) SVP exercises 40k options, sells shares - Stock Titan
Mirum Pharma (NASDAQ: MIRM) officer lines up $4M share sale - Stock Titan
MIRM Stock Clocks Best Day In 4.5 Months On Liver Disease Trial Data: Retail Eyes Buyout At A Premium - Stocktwits
Rice Hall James & Associates LLC Acquires New Position in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
TimesSquare Capital Management LLC Invests $43 Million in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals (MIRM) Q2 2026 Earnings Call Transcript - AOL.com
Will Mirum Pharmaceuticals' (MIRM) Widening Net Losses Test Its Growth-Focused Investment Narrative? - simplywall.st
Wall Street Zen Downgrades Mirum Pharmaceuticals (NASDAQ:MIRM) to Sell - MarketBeat
Why Mirum Pharmaceuticals (MIRM) Is Down 6.4% After Raising 2026 Sales Outlook Amid Wider Losses – And What's Next - Yahoo Finance
Janus Henderson Group (MIRM) reports 5.9M Mirum Pharma shares under management - Stock Titan
Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - The National Law Review
Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) CFO Sells 6,001 Shares of Stock - MarketBeat
Mirum Pharmaceuticals (MIRM) CFO sells 6,001 shares in Rule 10b5-1 trade - Stock Titan
Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Christopher Peetz Sells 20,000 Shares of Stock - MarketBeat
Mirum Pharmaceuticals CEO Christopher Peetz sells $1.98 million in shares By Investing.com - Investing.com Nigeria
Mirum Pharmaceuticals CEO Christopher Peetz sells $1.98 million in shares - Investing.com
Mirum Pharmaceuticals (MIRM) CEO trades 20,000 shares after option exercise under 10b5-1 plan - Stock Titan
(MIRM) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
MIRM (MIRM) insider files to sell 6,001 shares after recent stock sales - Stock Titan
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule - TradingView
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
What is HC Wainwright's Forecast for MIRM FY2026 Earnings? - MarketBeat
Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis: A 40% Potential Upside for Investors in Rare Disease Therapies - DirectorsTalk Interviews
Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM) and Encompass Health (EHC) - The Globe and Mail
MIRM (MIRM) insider Christopher Peetz plans 20,000-share sale after option exercise - Stock Titan
Hennion & Walsh Asset Management Inc. Sells 56,100 Shares of Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Q3 EPS Estimate for Mirum Pharmaceuticals Raised by Analyst - MarketBeat
TD Cowen Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $140 - Moomoo
Wall Street Zen Upgrades Mirum Pharmaceuticals (NASDAQ:MIRM) to "Hold" - MarketBeat
A Quick Look at Today's Ratings for Mirum Pharmaceuticals(MIRM.US), With a Forecast Between $118 to $140 - Moomoo
MIRUM PHARMACEUTICALS, INC. : RAYMOND JAMES RAISES TARGET PRICE TO $183 FROM $165 - webull.com
The Manufacturers Life Insurance Company Grows Stock Holdings in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Mirum Pharmaceuticals CEO Christopher Peetz sells $2.4 million in stock By Investing.com - Investing.com Nigeria
TD Cowen Cuts Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $140.00 - MarketBeat
Mirum Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $138.21, Implies 31% Upside - TradingView
Mirum Pharmaceuticals Slides as FDA Feedback Clouds Volixibat Timeline - Quiver Quantitative
Mirum's Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised - Yahoo Finance
Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Gap Down Following Weak Earnings - MarketBeat
FMR LLC reveals 6.2% Mirum Pharmaceuticals (MIRM) ownership in Schedule 13G - Stock Titan
RBC Capital Adjusts Mirum Pharmaceuticals PT to $135 From $148, Maintains Outperform Rating - marketscreener.com
HC Wainwright Cuts Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $140.00 - MarketBeat
Mirum Pharmaceuticals Inc (MIRM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Mirum Pharmaceuticals Inc 주식 (MIRM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Howe Jolanda | SVP, GLOBAL CONTROLLER |
Aug 18 '26 |
Sale |
100.00 |
40,000 |
4,000,000 |
1,274 |
0.86%
0.31%
자본화:
|
볼륨(24시간):